| 17.66 -0.48 (-2.65%) | 10-22 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 21.65  |
1-year : | 23.55 |
| Resists | First : | 18.53 |
Second : | 20.17 |
| Pivot price | 17.14 |
|||
| Supports | First : | 15.89 |
Second : | 13.22 |
| MAs | MA(5) : | 17.53  |
MA(20) : | 17.48 |
| MA(100) : | 16.35 |
MA(250) : | 12.9 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 55.9 |
D(3) : | 43.5 |
| RSI | RSI(14): 49.8 |
|||
| 52-week | High : | 21.7 | Low : | 3.42 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ URGN ] has closed below upper band by 23.0%. Bollinger Bands are 62.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 18.58 - 18.67 | 18.67 - 18.74 |
| Low: | 17.39 - 17.48 | 17.48 - 17.56 |
| Close: | 17.51 - 17.67 | 17.67 - 17.79 |
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Mon, 06 Oct 2025
UroGen Pharma Ltd.'s (NASDAQ:URGN) Price Is Out Of Tune With Revenues - simplywall.st
Tue, 09 Sep 2025
Breakeven On The Horizon For UroGen Pharma Ltd. (NASDAQ:URGN) - simplywall.st
Tue, 09 Sep 2025
Urogen Pharma (URGN) general counsel sells $29k in shares - Investing.com
Mon, 08 Sep 2025
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Mon, 18 Aug 2025
UroGen Pharma: Targeting Profits In 2027 (NASDAQ:URGN) - Seeking Alpha
Sun, 10 Aug 2025
UroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 46 (M) |
| Shares Float | 37 (M) |
| Held by Insiders | 6.8 (%) |
| Held by Institutions | 97.8 (%) |
| Shares Short | 8,720 (K) |
| Shares Short P.Month | 7,020 (K) |
| EPS | -3.06 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.02 |
| Profit Margin | -164.5 % |
| Operating Margin | -171.2 % |
| Return on Assets (ttm) | -31.3 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 10.8 % |
| Gross Profit (p.s.) | 1.8 |
| Sales Per Share | 2.03 |
| EBITDA (p.s.) | -2.65 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -123 (M) |
| Levered Free Cash Flow | -61 (M) |
| PE Ratio | -5.78 |
| PEG Ratio | 0 |
| Price to Book value | -8.75 |
| Price to Sales | 8.66 |
| Price to Cash Flow | -6.64 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|